Status:

UNKNOWN

Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection

Lead Sponsor:

Tel-Aviv Sourasky Medical Center

Conditions:

SARS-CoV-2

Eligibility:

All Genders

18-85 years

Phase:

PHASE1

Brief Summary

This is an open-label Phase I study, four dose escalation groups, to evaluate the safety of CD24-exosomes in patients with moderate/severe COVID-19 disease. Patients with moderate/severe COVID-19 inf...

Detailed Description

Coronavirus disease 2019 (COVID-19) is a highly transmissible disease in the community. The main cause of clinical deterioration that leads to death is the cytokine storm in the lung. CD24 is a small...

Eligibility Criteria

Inclusion

  • A COVID-19 diagnosis confirmed with a SARS-CoV-2 viral infection positive polymerase chain reaction (PCR) test
  • Disease severity: Moderate/severe according to the following criteria (at least one clinical parameter and one laboratory parameter are required):
  • Clinical and Imaging-based evaluation
  • Respiratory rate \> 23/ min and \< 30/min
  • SpO2 at room air ≤94% and ≥90%
  • Bilateral pulmonary infiltrates \>50% within 24-48 hours or a severe deterioration compared to imaging at admission
  • Evidence of an exacerbated inflammatory process
  • LDH score \> 450 u/L
  • CRP \>100 u/L
  • Ferritin \>1650 ng/ml
  • Lymphopenia \<800 cells/mm3 v. D-dimers\>1
  • Willing and able to sign an informed consent
  • Exclusion Criteria:
  • Age\<18 years or \>85 years
  • Any concomitant illness that, based on the judgment of the Investigator is terminal
  • Ventilated patient
  • Pregnancy (positive urine pregnancy test \[women of childbearing potential only\]) or breastfeeding
  • Unwilling or unable to provide informed consent
  • Participation in any other study in the last 30 days

Exclusion

    Key Trial Info

    Start Date :

    September 25 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 25 2021

    Estimated Enrollment :

    35 Patients enrolled

    Trial Details

    Trial ID

    NCT04747574

    Start Date

    September 25 2020

    End Date

    March 25 2021

    Last Update

    March 4 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Tel Aviv Medical Center

    Tel Aviv, Israel